Janney Montgomery Scott LLC Makes New Investment in Oscar Health, Inc. (NYSE:OSCR)

Janney Montgomery Scott LLC purchased a new position in shares of Oscar Health, Inc. (NYSE:OSCR) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 46,568 shares of the company’s stock, valued at approximately $988,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OSCR. Swiss National Bank lifted its holdings in Oscar Health by 2.4% in the first quarter. Swiss National Bank now owns 263,800 shares of the company’s stock valued at $3,923,000 after acquiring an additional 6,100 shares during the period. Sei Investments Co. boosted its holdings in Oscar Health by 100.0% in the 1st quarter. Sei Investments Co. now owns 42,998 shares of the company’s stock valued at $639,000 after purchasing an additional 21,497 shares during the last quarter. ProShare Advisors LLC raised its position in Oscar Health by 10.9% in the first quarter. ProShare Advisors LLC now owns 28,950 shares of the company’s stock valued at $430,000 after purchasing an additional 2,842 shares during the period. Jupiter Asset Management Ltd. acquired a new position in Oscar Health in the first quarter valued at about $653,000. Finally, Vanguard Group Inc. boosted its position in shares of Oscar Health by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 14,582,762 shares of the company’s stock worth $216,846,000 after purchasing an additional 337,850 shares during the period. 75.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Oscar Health news, Director Thrive Partners Vii Growth Gp, bought 420,819 shares of the stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $13.68 per share, with a total value of $5,756,803.92. Following the purchase, the director now directly owns 5,452,081 shares in the company, valued at $74,584,468.08. The trade was a 8.36 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mario Schlosser sold 3,198 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $17.99, for a total transaction of $57,532.02. Following the completion of the sale, the insider now directly owns 76,982 shares of the company’s stock, valued at $1,384,906.18. This trade represents a 3.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 1,055,478 shares of company stock worth $14,432,852 and have sold 169,569 shares worth $3,007,069. Corporate insiders own 25.11% of the company’s stock.

Oscar Health Price Performance

Shares of OSCR opened at $14.87 on Friday. The company has a current ratio of 0.73, a quick ratio of 0.91 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average of $18.20 and a 200-day moving average of $18.27. Oscar Health, Inc. has a 52 week low of $6.93 and a 52 week high of $23.79. The firm has a market cap of $3.60 billion, a price-to-earnings ratio of -247.83 and a beta of 1.67.

Oscar Health (NYSE:OSCR) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02). The business had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.33 billion. Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The company’s quarterly revenue was up 68.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) earnings per share. As a group, analysts forecast that Oscar Health, Inc. will post -0.01 EPS for the current year.

Analyst Ratings Changes

OSCR has been the subject of several recent research reports. UBS Group started coverage on shares of Oscar Health in a research report on Monday, October 7th. They issued a “neutral” rating and a $23.00 price target for the company. Bank of America downgraded Oscar Health from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $21.00 to $13.50 in a report on Wednesday, November 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $28.00 price objective on shares of Oscar Health in a research note on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Oscar Health currently has an average rating of “Moderate Buy” and a consensus price target of $22.93.

Oscar Health Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.